Search Within

Charles Rudin

Formats
  1. Journal Article (245)
  2. Meeting Abstract (223)
  3. Review (11)
  4. Editorial (10)
  5. Book Section (3)
  6. Guidelines (2)
  7. Research Letter (2)
  8. Correspondence (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (497)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (497)
  3. Department of Medicine (497)
  4. GSK Faculty (497)
  5. Solid Tumor Oncology Division (497)
  6. Thoracic Oncology (497)

More Groups

People
  1. Mark Kris (100)
  2. Natasha Rekhtman (96)
  3. Marc Ladanyi (93)
  4. Gregory Riely (76)
  5. Bob Li (72)
  6. Elisa De Stanchina (70)

More People

Years
  1. 2025 (20)
  2. 2024 (48)
  3. 2023 (43)
  4. 2022 (59)
  5. 2021 (52)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (83)
  2. Journal of Thoracic Oncology (79)
  3. Clinical Cancer Research (34)
  4. Cancer Research (31)
  5. Annals of Oncology (30)
  6. Cancer Discovery (15)

More Publications

Publishers
  1. Elsevier Inc. (105)
  2. American Society of Clinical Oncology (93)
  3. American Association for Cancer Research (87)
  4. Nature Publishing Group (45)
  5. Oxford University Press (40)
  6. Cell Press (28)

More Publishers

Results (497)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MET inhibitor resistance in patients with MET exon 14-altered lung cancers
    Meeting Abstract

    Guo, R.; Offin, M.; Brannon, A. R.; Chow, A.; Delasos, L.; Somwar, R.; Wilkins, O.; Scott, K.; Tian, Y.; Cecchi, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Inherited truncating RAD52 variant discovered using integrated germline-somatic analysis predicts clinical outcome in patients with lung cancers
    Meeting Abstract

    Mukherjee, S.; Srinivasan, P.; Bandlamudi, C.; Hellmann, M. D.; Ravichandran, V.; Selvan, M. E.; Kemel, Y.; Mandelker, D.; Zauderer, M.; Walsh, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Characterization of SLFN11 protein expression in circulating tumor cells (CTCs) of patients with metastatic castration resistant prostate cancer (mCRPC) prior to platinum based chemotherapy
    Meeting Abstract

    Fernandez, L.; Poirier, J.; Rodriguez, A.; Hulling, M.; Richardson, R.; Sutton, R.; Jiles, R.; Schonhoft, J.; Lee, J.; Ebrahim, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Tim-4(+) tissue-resident macrophages impair antitumor T-cell immunity
    Meeting Abstract

    Chow, A.; Schad, S.; Sharma, S. K.; Budhu, S.; Gupta, A.; Pimentel, C.; Zhong, H.; Lewis, J. S.; Poirier, J. T.; Wolchok, J. D.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Direct genome editing of patient-derived xenografts for rapid in vivo functional genomics
    Meeting Abstract

    Hulton, C. H.; Costa, E. A.; Rudin, C. M.; Poirier, J. T.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Circulating tumor DNA profiling in small-cell lung cancer identifies potentially targetable alterations
    Journal Article

    Devarakonda, S.; Sankararaman, S.; Herzog, B. H.; Gold, K. A.; Waqar, S. N.; Ward, J. P.; Raymond, V. M.; Lanman, R. B.; Chaudhuri, A. A.; Owonikoko, T. K.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Evaluation of H3K27me3 expression as a marker of EZH2 activation in SMARCA4/SMARCA2-deficient tumors and candidate biomarker for trials of EZH2 inhibitors
    Meeting Abstract

    Kezlarian, B.; Montecalvo, J.; Sauter, J.; Travis, W.; Gounder, M.; Rudin, C.; Ladanyi, M.; Namakydoust, A.; Rekhtman, N.
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
    Journal Article

    Offin, M.; Chan, J. M.; Tenet, M.; Rizvi, H. A.; Shen, R.; Riely, G. J.; Rekhtman, N.; Daneshbod, Y.; Quintanal-Villalonga, A.; Penson, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Positron-emission tomographic imaging of a fluorine 18-radiolabeled Poly(ADP-ribose) polymerase 1 inhibitor monitors the therapeutic efficacy of talazoparib in SCLC patient-derived xenografts
    Journal Article

    Laird, J.; Lok, B. H.; Carney, B.; Kossatz, S.; de Stanchina, E.; Reiner, T.; Poirier, J. T.; Rudin, C. M.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Evaluation of H3K27me3 expression as a marker of EZH2 activation in SMARCA4/SMARCA2-deficient tumors and candidate biomarker for trials of EZH2 inhibitors
    Meeting Abstract

    Kezlarian, B.; Montecalvo, J.; Sauter, J.; Travis, W.; Gounder, M.; Rudin, C.; Ladanyi, M.; Namakydoust, A.; Rekhtman, N.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save